Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 1997

Treatment of Bulimia Nervosa With Ondansetron

Author Affiliations

University of Minnesota Medical School—Minneapolis 420 Delaware St SE Minneapolis, MN 55455

Arch Gen Psychiatry. 1997;54(10):969-970. doi:10.1001/archpsyc.1997.01830220099014

Bulimia nervosa, a chronic psychiatric disorder, is characterized by frequent episodes of binge eating followed by purging (usually in the form of self-induced vomiting) with a loss of volitional control over these behaviors. This disorder occurs in 3% to 5% of young women.1 Our research group has previously suggested that the pathophysiological characteristics driving the abnormal behaviors involve an increase in the basal tone of the vagus nerve as a result of repeated and aggressive stimulation of the gastric branch of the vagus nerve by binge eating and vomiting.2 This hypothesis led us to treat a total of 5 women who met the DSM-III-R criteria for bulimia nervosa (binge-purge subtype) with ondansetron hydrochloride (a 5-hydroxytryptamine type 3 receptor antagonist that pharmacologically decreases vagal transmission3). All of these patients were considered to have severe bulimia nervosa due to the chronicity of the disease, a history of previous drug

First Page Preview View Large
First page PDF preview
First page PDF preview